Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 29 January 2026 - 5 February 2026

Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

Cigna shares rose 3.2% to $280.46 after posting Q4 adjusted earnings of $8.08 per share, above forecasts, though its 2026 outlook missed estimates. Express Scripts agreed to a 10-year FTC settlement on insulin pricing, expected to cut patient costs by up to $7 billion. Evernorth pharmacy revenue jumped 20% to $36.3 billion. Cigna’s board raised its quarterly dividend to $1.56 per share.
5 February 2026
···
Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly shares surged about 9% Wednesday after reporting a 43% jump in quarterly revenue to $19.3 billion and issuing a bullish 2026 outlook. Mounjaro and Zepbound drove results, but executives warned pricing will weigh on future growth. Investors await the FDA’s April decision on Lilly’s oral obesity drug. The stock’s rally contrasted with declines in major indexes.
4 February 2026
···
Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer shares rose 3.7% to $26.73 Wednesday after reporting Phase 2b trial results showing up to 12.3% placebo-adjusted weight loss at 28 weeks for its obesity drug PF’3944. The company reaffirmed its 2026 revenue and profit targets and said it will not pursue share buybacks. Pfizer reported Q4 adjusted EPS of 66 cents on $17.6 billion revenue. Full VESPER-3 results will be released June 6.
4 February 2026
··
Zurich’s £8bn Beazley bid jolts FTSE 100 to a fresh record as GSK rallies, AI fears hit data stocks

Zurich’s £8bn Beazley bid jolts FTSE 100 to a fresh record as GSK rallies, AI fears hit data stocks

Zurich Insurance has proposed to buy Beazley for up to 1,335 pence per share, valuing the deal at about £8 billion. Beazley’s board said it would support the offer if Zurich makes a firm bid by Feb. 16. Beazley shares rose 9% on the news. The FTSE 100 hit a new intraday high, with GSK up and Relx and LSEG under pressure from AI concerns.
4 February 2026
·····
AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie shares rose 0.8% to $227.55 Tuesday afternoon ahead of its quarterly earnings report due Wednesday morning. The company filed with U.S. and European regulators to expand Rinvoq’s use to non-segmental vitiligo, based on Phase 3 data. Investors are watching whether new immunology drugs can offset Humira’s sales decline.
3 February 2026
···
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio shares (IBRX) closed Friday up 6% at $6.25, bucking broader market declines. The company faces dilution risk after amending a $505 million convertible note with Nant Capital. Attention is on FDA feedback for ANKTIVA’s label expansion in papillary bladder cancer, with a regulatory submission expected within 30 days. The next major event is the late-February ASCO GU conference.
1 February 2026
··
Merck stock jumps to $110 as MRK heads into a big earnings week

Merck stock jumps to $110 as MRK heads into a big earnings week

Merck shares rose 1.8% to $110.27 Friday, outperforming a falling S&P 500 and closing about 2% below their 52-week high. Trading volume topped 19 million shares, well above rivals. Investors await Merck’s Feb. 3 earnings call and new inflation data that could affect rate expectations. Markets reacted to President Trump’s Fed pick and mixed inflation signals.
31 January 2026
···
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics shares rose 3.7% to $21.62 Thursday after the FDA halted Regenxbio’s gene therapy trials over a brain tumor case, intensifying focus on Denali’s Hunter syndrome drug under FDA review. Investors await Denali’s clinical data update in early February and a regulatory decision by April 5. The iShares Nasdaq Biotechnology ETF was little changed.
29 January 2026
····
1 2 3 … 12

Stock Market Today

IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

IRS tax refund delays? Watchdog flags staffing crunch as 2026 filing season ramps up

7 February 2026
IRS staffing has dropped to 2021 levels as the 2026 tax filing season begins, according to a Treasury watchdog. The agency faces a backlog of about 2 million returns, 129% above pre-pandemic levels. Most e-filers using direct deposit still get refunds within 21 days, but paper filings and amended returns could see delays. The IRS lowered its call-answer target to 70% for this season.
Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

Plug Power stock jumps 12% after vote setback, with Feb 17 share decision in focus

7 February 2026
Plug Power shares rose 11.6% Friday to $2.08 after a sharp drop the previous day, as attention shifted to a Feb. 17 shareholder vote on expanding authorized shares. The company failed to secure enough votes earlier this week and is urging overseas holders to participate. CEO Andy Marsh cited difficulties for European investors in casting ballots. A reverse stock split remains possible if the proposal fails.
AT&T stock price: T slips after $6.5B bond sale as payrolls, CPI loom next week

AT&T stock price: T slips after $6.5B bond sale as payrolls, CPI loom next week

7 February 2026
AT&T shares closed down 0.7% at $27.13 on Friday, underperforming the S&P 500’s 1.97% gain. The company completed a $6.5 billion global notes sale this week, with maturities from 2031 to 2056 and coupons between 4.4% and 6%. Investors await delayed U.S. jobs and inflation data, along with T-Mobile’s upcoming earnings update.
Go toTop